若生智能
Drug Database
BR

Brizantin (Brizantin)

✓ Approved

Materia Medica Holding · CNR1 · 单克隆抗体

什么是 Brizantin？

Brizantin 是一种单克隆抗体，由Materia Medica Holding研发。该药已获批，用于治疗相关适应症，给药途径：Oral (PO)。

药物档案

商品名Brizantin
公司Materia Medica Holding
药物类别单克隆抗体, 抗体
分子靶点CNR1
给药途径Oral (PO)
状态Approved
来源： ClinicalTrials.gov, Materia Medica Holding

作用机制

分子靶点

Brizantin 作用于 1 个分子靶点：

CNR1cannabinoid receptor 1 (CNR, CB1A)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

Brizantin 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Psychiatric disordersNicotine dependence✓ Approved

相关研究文献

PubMedDose-response : a publication of International Hormesis Society2018-07-18

Dose-Response Effect of Antibodies to S100 Protein and Cannabinoid Receptor Type 1 in Released-Active Form in the Light-Dark Test in Mice.

Kardash Elena V EV, Ertuzun Irina A IA, Khakimova Gul'nara R GR, Kolyadin Andrey N AN et al.

Earlier studies have shown that combination of antibodies to S100 protein and to cannabinoid receptor type 1 in released-active form (Brizantin) may possess anxiolytic properties and decrease nicotine dependence. Released-active form of antibodies is a novel approach that permits to modify natural functions of the target molecule (antigen) under investigation. The aim of the present study was to evaluate the anxiolytic-like effect of Brizantin in the light-dark test in mice, according to its ability to influence the number of entries into the lit compartment and the total time spent there. Three doses of Brizantin (2.5, 5, and 10 mL/kg) were compared with diazepam (1 mg/kg), placebo, and vehicle control. Anxiolytic-like effect of the tested drug was shown to be dose dependent, with an increasing trend from 2.5 to 10 mL/kg. Brizantin in its highest dose significantly increased studied behavioral parameters, although its effect was less pronounced than that of the reference drug diazepam (1 mg/kg).

PMID 30013455
阅读全文 →
PubMedZhurnal nevrologii i psikhiatrii imeni S.S. Korsakova2016-07-08

[Farmacological effects of anti-S 100 in release-active form and mechanisms of their realization].

Khakimova G R GR, Voronina T A TA, Dugina Yu L YL, Ertuzun I A IA et al.

Antibodies to 5100 proteins (anti-5100) in release-active form (RA anti-5100) are an active component of some domestic drugs(tenoten, tenoten for children, divaza, brizantin, kolofort and proproten-100). The authors present the results of preclinical and clinical trials (with detailed consideration of experimental data) which demonstrated a wide spectrum of specific pharmacological activity and safety as well as mechanisms of anti-5100 action.

PMID 27386593
阅读全文 →
PubMedBulletin of experimental biology and medicine2015-11-27

The Use of Release-Active Antibody-Based Preparations for Vertigo Prevention in Adults.

Barchukov V V VV, Zhavbert E S ES, Dugina Yu L YL, Epstein O I OI

The effectiveness of antibody-based release-active preparations Impaza (antibodies to eNOS), Tenoten (antibodies to brain-specific protein S-100), Dietressa (antibodies to type 1 cannabinoid receptor), Brizantin (combined preparation, antibodies to brain-specific protein S-100 and type 1 cannabinoid receptor), and Divaza (combined preparation, antibodies to brain-specific protein S-100 and eNOS) in the prevention of vertigo was studied on the model of intermittent accumulation of Coriolis accelerations (ICCA). Modification of activity of vestibular receptors and signal systems by release-active preparations contributed to an increase in ICCA tolerance time. Combined preparation Impaza possessed the most significant antinaupathic properties. Brizantin was less potent in this respect.

PMID 26608378
阅读全文 →
PubMedBulletin of experimental biology and medicine2015-11-01

Anxiolytic and Antidepressant Effects of Divaza and Brizantin.

Yakovleva N N NN, Voronina T A TA, Suslov N I NI, Ertuzun I A IA et al.

The anxiolytic and antidepressant activities of complex preparations divaza and brizantin containing antibodies to brain-specific protein S100 were estimated using Vogel conflict test and Nomura forced swimming test. Course treatment (5 days) of brizantin in a dose of 2.5 ml/kg and divaza in a dose of 7.5 ml/kg significantly increased punished drinking in the Vogel conflict test in comparison with the control. Both drugs also improved general emotional behavior during training prior to the test procedure. Brizantin and divaza in a dose of 7.5 ml/kg increased the number of wheel revolutions in the Nomura forced swimming test in comparison with the control; the effect of divaza was more pronounced. High correlation coefficients between the number of wheel revolutions during the first and second 5-min sessions are also indicative of antidepressant action of divaza and brizantin.

PMID 26519263
阅读全文 →
PubMedBulletin of experimental biology and medicine2013-03-14

Experimental study on the efficacy of the drug Brizantin in the model of nicotine dependence.

Kheyfets I A IA, Vorob'eva T M TM, Veselovskaya E V EV, Shlyahova A V AV et al.

We estimated the efficacy of Brizantin preparation in suppressing nicotine dependence in rats. It was shown that nicotine-dependent rats in the situation of choice between the chamber with smoke or the chamber with food more frequently entered the chamber with tobacco smoke and stayed there longer. The rats that received Brizantin demonstrated significantly fewer visits to the chamber with smoke and spent there less time. Reduced locomotor activity and orientation and exploratory behavior in rats against the background of Brizantin administration also suggest reduced motivation for smoke inhalation. Thus, Brizantin effectively diminished nicotine dependence in rats in the model of nicotine addiction.

PMID 23484195
阅读全文 →

注册免费账户还可查看另外 1 篇文献

免费注册查看全部文献 →

了解更多Brizantin